| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Ligand Pharmaceuticals Inc (LGND) has 11 insiders with recent SEC Form 4 filings, including 0 buys and 11 sells. LGND is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 161.3K | $35.72M | - | |
| Dir | 44.0K | $9.74M | - | |
| Dir | 33.8K | $7.48M | - | |
| Dir | 32.8K | $7.25M | - | |
| Other | 30.8K | $6.82M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Feb 23, 2018 | Aryeh Jason | Director | Sell | 3,417 | $155.00 | $529,635.00 | -3.8% | |
| Feb 23, 2018 | Foehr Matthew W72 | President And COO | Sale+OE | 5,444 | $152.98 | $832,823.66 | -5.4% | |
| Feb 15, 2018 | Higgins John L66 | Chief Executive Officer | Sell | 9,000 | $157.03 | $1,413,279.00 | -8.1% | |
| Jan 24, 2018 | Higgins John L66 | Chief Executive Officer | Sell | 22,500 | $165.00 | $3,712,500.00 | -16.8% | |
| Jan 19, 2018 | Higgins John L66 | Chief Executive Officer | Sale+OE | 28,099 | $153.70 | $4,318,901.51 | -9.1% | |
| Jan 10, 2018 | Kozarich John W61 | Director | Sell | 2,500 | $145.00 | $362,500.00 | -7.0% | |
| Dec 20, 2017 | Sabba Stephen L | Director | Sell | 925 | $137.25 | $126,956.25 | -3.3% | |
| Nov 17, 2017 | Aryeh Jason | Director | Sell | 24,400 | $140.22 | $3,421,368.00 | -21.3% | |
| Nov 17, 2017 | Higgins John L66 | Chief Executive Officer | Sell | 2,258 | $140.34 | $316,887.72 | -1.6% | |
| Nov 17, 2017 | Lamattina John L | Director | Sale+OE | 4,000 | $139.79 | $559,160.00 | -16.0% |